These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20879028)

  • 1. The next step for taribavirin.
    Kwo PY; Vinayek R
    Hepatology; 2010 Oct; 52(4):1185-8. PubMed ID: 20879028
    [No Abstract]   [Full Text] [Related]  

  • 2. Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.
    Gish RG; Arora S; Rajender Reddy K; Nelson DR; O'Brien C; Xu Y; Murphy B
    J Hepatol; 2007 Jul; 47(1):51-9. PubMed ID: 17470380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taribavirin in the treatment of hepatitis C.
    Deming P; Arora S
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1435-43. PubMed ID: 21854301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
    Poordad F; Lawitz E; Shiffman ML; Hassanein T; Muir AJ; Bacon BR; Heise J; Halliman D; Chun E; Hammond J
    Hepatology; 2010 Oct; 52(4):1208-15. PubMed ID: 20721883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribavirin analogs.
    Shields WW; Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):419-27. PubMed ID: 19628158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
    Kasahara A
    J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
    [No Abstract]   [Full Text] [Related]  

  • 7. Taribavirin for the treatment of chronic hepatitis C.
    Kearney KR; Thornton JJ; Navarro VJ
    Expert Opin Pharmacother; 2008 Dec; 9(18):3243-9. PubMed ID: 19040344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribavirin-induced hemolytic anemia in chronic hepatitis C patients.
    Itoh Y; Okanoue T
    J Gastroenterol; 2004 Jul; 39(7):704-5. PubMed ID: 15293148
    [No Abstract]   [Full Text] [Related]  

  • 9. Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.
    Demelia L; Civolani A; Murgia D; Murru A; Sorbello O; Rizzetto M
    J Hepatol; 2007 Jan; 46(1):171-3. PubMed ID: 17107736
    [No Abstract]   [Full Text] [Related]  

  • 10. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
    Oze T; Hiramatsu N; Kurashige N; Tsuda N; Yakushijin T; Kanto T; Takehara T; Kasahara A; Kato M; Yoshihara H; Katayama K; Kubota S; Hijioka T; Ishibashi K; Oshita M; Hagiwara H; Haruna Y; Mita E; Tamura S; Hayashi N
    J Gastroenterol; 2006 Sep; 41(9):862-72. PubMed ID: 17048050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C.
    Doehring A; Hofmann WP; Schlecker C; Zeuzem S; Sarrazin C; Berg T; Müller T; Herrmann E; Geisslinger G; Lötsch J
    Pharmacogenet Genomics; 2011 May; 21(5):289-96. PubMed ID: 21346688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.
    De Franceschi L; Fattovich G; Turrini F; Ayi K; Brugnara C; Manzato F; Noventa F; Stanzial AM; Solero P; Corrocher R
    Hepatology; 2000 Apr; 31(4):997-1004. PubMed ID: 10733558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    J Gastroenterol; 2004 Nov; 39(11):1090-4. PubMed ID: 15580403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.
    Brochot E; Castelain S; Duverlie G; Capron D; Nguyen-Khac E; François C
    Antivir Ther; 2010; 15(5):687-95. PubMed ID: 20710050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
    Durante Mangoni E; Marrone A; Saviano D; Del Vecchio C; Utili R; Ruggiero G
    Antivir Ther; 2003 Feb; 8(1):57-63. PubMed ID: 12713065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
    Orāşan O; Cozma A; Rednic N; Sâmpelean D; Pârvu A; Petrov L
    Rom J Intern Med; 2009; 47(3):217-25. PubMed ID: 20446436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions.
    Dev A; Patel K; Muir A; McHutchison JG
    Am J Gastroenterol; 2003 Nov; 98(11):2344-7. PubMed ID: 14638332
    [No Abstract]   [Full Text] [Related]  

  • 18. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.
    McHutchison JG; Manns MP; Brown RS; Reddy KR; Shiffman ML; Wong JB
    Am J Gastroenterol; 2007 Apr; 102(4):880-9. PubMed ID: 17397412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hepatitis C: therapeutic management].
    Bourliere M
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 2):S166-71. PubMed ID: 18482813
    [No Abstract]   [Full Text] [Related]  

  • 20. Should ribavirin be used to treat hepatitis C in dialysis patients?
    Carrion AF; Fabrizi F; Martin P
    Semin Dial; 2011; 24(3):272-4. PubMed ID: 21480995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.